Skip to content
‹ Back to IndustriesHealthcare

Researchers: Viruses Like COVID-19 Can Be Prevented With the Development of a Targeted Nasal Spray Solution

Scientists identify viral entry points in the respiratory system, opening a path toward non-invasive prevention strategies

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Radwa Ewaisha · · Alexandria UniversityCovid-19Dr. Radwa Emad EwaishaFaculty of Pharmacy
Share

Key takeaways

01

Scientists identify viral entry points in the respiratory system, opening a path toward non-invasive prevention strategies

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

As the world continues to grapple with the ongoing COVID-19 pandemic, scientists are not just working on vaccines and treatments but also on preventive measures that could be simpler yet effective. Imagine a world where a spritz of a nasal spray could help you fight the virus? That notion isn’t just wishful thinking; it’s grounded in intensive research into the anatomy of our respiratory system. Scientists have identified the ports of entry that SARS-CoV-2 exploits to initiate an infection. Once these entry points are known, it becomes possible to develop targeted interventions, specifically targeting the nose. Such a preventive measure could be revolutionary. And not only in combating COVID-19, but also in preparing us for future pandemics of respiratory viruses.

Such a preventive measure could be revolutionary. And not only in combating COVID-19, but also in preparing us for future pandemics of respiratory viruses.

Detailing more on this exciting frontier is Dr. Radwa Emad Ewaisha, Assistant Professor of Microbiology and Immunology at the Faculty of Pharmacy at Alexandria University.

Upon conclusion of recent research exploring nose cells, she added that the development of a nasal solution as a shield against viral infections could be a preventative measure for other possible viral infections. Dr. Ewaisha also stated that this nasal cell research will be groundbreaking for the pharmaceutical industry.

Dr. Radwa Emad Ewaisha has been teaching and conducting research at the Faculty of Pharmacy at Alexandria University since January 2019. She earned her Ph.D. in Cellular and Molecular Biology from Arizona State University. Additionally, she also obtained a Master’s there in the same field. Dr. Ewaisha also completed a Clinical Chemistry Post-PhD Fellowship at the prestigious Mayo Clinic School of Medicine. Prior to her doctorate, she earned a Master’s degree in Pharmaceutical Sciences focusing on Pharmaceutical Microbiology from Alexandria University.

Dr. Ewaisha's Thoughts on a Nasal Spray Solution

"These researchers studied cells that line the nose and airway, and they studied the microstructures that are found on these cells, such as cilia and microvilli. They were then able to identify the specific ports of entry in our noses that SARS-CoV-2 uses to start an infection. This means that, in theory, a prophylactic nasal spray can be developed, especially one that can be used following a suspected exposure to the virus, and this has very important implications not only for COVID, but potentially for future pandemics as well.

In theory, a prophylactic nasal spray can be developed, especially one that can be used following a suspected exposure to the virus, and this has very important implications not only for COVID, but potentially for future pandemics as well.
— Dr. Radwa Emad Ewaisha, Assistant Professor of Microbiology and Immunology at Faculty of Pharmacy at Alexandria University

"This study has identified targets in these cells that, when inhibited, this can actually prevent respiratory viruses from establishing a stronghold in our nose or throat and spreading the infection to neighboring cells. These targets provide new avenues for pharmaceutical companies to develop and market a prophylactic nasal spray that can abort the infection."

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

Radwa Ewaisha
Radwa EwaishaAssistant Professor of Microbiology and Immunology

Scientist, Pharmacist, YouTuber, Podcaster, Assistant Professor of Microbiology and Immunology who loves to communicate science in different languages.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Epic's seven bets beyond the EHR, sorted by when hospitals can actually use them

Epic's seven bets beyond the EHR, sorted by when hospitals can actually use them

Epic is expanding past its EHR into ERP, IT staffing, AI, drug pricing and payer technology. Delivery runs from tools live today to a full EpicOps rollout that may not arrive until 2029. The payer platform has the clearest proof point: St. Luke's and UnitedHealthcare automated status updates on 88% of the claims they exchanged.

  • 01Epic's payer platform is the expansion bet with a measured result: 88% of claim status updates automated between St. Luke's and UnitedHealthcare, plus a 25% drop in status calls.
  • 02EpicOps, Epic's ERP suite, may not be fully available until 2029, so a health system whose ERP commitments end sooner can test individual modules alongside its current system without a full switch.
  • 03Before buying any third-party app that has to work inside Epic, ask the vendor to demonstrate the exact write operation it needs in your own environment, because FHIR support alone does not guarantee write access.

Nov 16, 2026

Avanlee Care’s $3.5M seed tests whether Medicare Advantage plans will pay to reach caregivers

Avanlee Care’s $3.5M seed tests whether Medicare Advantage plans will pay to reach caregivers

Avanlee Care raised a $3.5 million seed round led by BEA Venture Fund, bringing total funding to $6 million. The startup helps Medicare Advantage plans find and support members' family caregivers. Its bet: plans will pay to reach whoever books the visits.

  • 01Medicare Advantage plans can see overdue visits and refills; Avanlee Care’s $3.5M seed backs a per-member-per-month model to reach the family caregiver who can act on that outreach.
  • 02Caregiver support among Medicare Advantage Special Needs Plans rose from 5% of plans in 2025 to 16% in 2026, even as meals and transportation benefits declined. That gives benefit designers a reference point.

Nov 15, 2026

Oura's $625 million Counsel Health deal puts a ring maker in the triage business

Oura's $625 million Counsel Health deal puts a ring maker in the triage business

Oura is buying Counsel Health for $625 million in cash, bringing an AI chat service with on-demand physicians in-house. Counsel will keep selling triage and virtual care to health plans, health systems and employers. Outcomes data is still to come.

  • 01For $625 million in cash, a smart ring company now owns a service pitched to health plans as a replacement for the nurse triage line.
  • 02Counsel's website offers a free conversation with Counsel AI and lets users add a doctor for $29, a public reference point benefits teams could use when comparing virtual care costs.
  • 03The evidence behind the combined model is member satisfaction (4.6 out of 5) and self-reported surveys; clinical outcomes and cost results are the numbers that would confirm it.

Nov 15, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

Radwa Ewaisha
Radwa Ewaisha

Assistant Professor of Microbiology and Immunology

Scientist, Pharmacist, YouTuber, Podcaster, Assistant Professor of Microbiology and Immunology who loves to communicate science in different languages.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512